Kura Oncology, Inc. — Form 10-K Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing precision oncology medicines for genetically defined cancers. This Form 10-K covers the fiscal year ended December 31, 2020, and was filed February 24, 2021. The company had no approved products and no product sales revenue.
- Lead programs: tipifarnib, a farnesyl transferase inhibitor, and KO-539, a menin-KMT2A inhibitor.
- Tipifarnib was being evaluated principally in HRAS-mutant head and neck squamous cell carcinoma through the AIM-HN registration-directed trial and other studies.
- KO-539 was in the Phase 1/2 KOMET-001 trial for relapsed or refractory acute myeloid leukemia.
- The company employed 89 people at year-end, including 88 full-time employees.
Financial and operating metrics
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Product revenue | None | None | Not applicable |
| Research and development expense | $60.4 million | $47.8 million | +$12.6 million |
| General and administrative expense | $31.5 million | $19.7 million | +$11.8 million |
| Total operating expenses | $91.9 million | $67.5 million | +$24.4 million |
| Other income, net | $2.3 million | $4.3 million | -$2.1 million |
| Net loss | $89.6 million | $63.1 million | Loss increased $26.5 million |
| Basic and diluted net loss per share | $1.69 | $1.51 | Loss per share increased |
| Net cash used in operating activities | $69.8 million | $54.8 million | Use increased $15.1 million |
| Cash, cash equivalents and short-term investments | $633.3 million | $236.9 million | Increased $396.4 million |
Research and development spending increased primarily because of higher KO-539 clinical-trial and manufacturing costs, discovery-stage activities, and personnel and support costs. Tipifarnib-related costs were broadly stable at $26.0 million versus $26.5 million in 2019. KO-947 costs declined following termination of that program.
At December 31, 2020, total assets were $647.2 million, total liabilities were $36.3 million, and stockholders’ equity was $610.9 million. The accumulated deficit was $302.5 million. The company reported no income tax expense because deferred tax assets were fully offset by a valuation allowance.
Debt consisted primarily of a $7.25 million SVB term loan, including $3.0 million classified as current and $4.25 million classified as long-term. The loan bears interest at the greater of 5.50% or prime plus 0.25%, matures May 1, 2023, and is secured by substantially all assets other than intellectual property. The company was in compliance with its covenants at year-end.
Material changes versus the prior comparable period
- Net loss increased 42% from $63.1 million to $89.6 million as operating expenses expanded.
- R&D expense increased 26%, while G&A expense increased 60%, reflecting clinical development, pre-commercial planning, personnel, professional services and share-based compensation.
- Operating cash burn increased to $69.8 million from $54.8 million.
- Financing cash inflows rose to $469.3 million from $111.1 million, principally due to May and December 2020 public offerings that generated aggregate net proceeds of approximately $459.0 million.
- Cash and investments increased materially, supporting management’s stated expectation that available resources would fund operations and capital requirements into 2024 based on current plans.
- The company amended AIM-HN in July 2020 to permit enrollment of patients with any HRAS mutation and to reflect evolving standards of care. The amendments increased the number of evaluable patients required and delayed the expected enrollment timeline.
- In May 2020, the company suspended planned registration-directed tipifarnib development in T-cell lymphoma and a planned pancreatic cancer Phase 2 study, and terminated the KO-947 ERK inhibitor program.
Clinical results, guidance and outlook
- In the RUN-HN Phase 2 study, 18 patients were evaluable for efficacy; nine achieved partial responses, for a 50% objective response rate. Median duration of response was 14.7 months, median progression-free survival was 5.9 months, and median overall survival was 15.4 months. These results were investigator-assessed and may not predict results from AIM-HN.
- AIM-HN enrollment was affected by COVID-19 and the protocol amendments. Management stated it could not reasonably forecast when the trial would become fully enrolled.
- KO-539 preliminary KOMET-001 data included six patients with clinical or biological activity among eight efficacy-evaluable patients, including two complete remissions and one morphological leukemia-free state. The data cutoff was November 2, 2020, and the results were preliminary.
- KO-539 had no treatment-related discontinuations and no reported QTc prolongation at the data cutoff, but grade 3 or higher treatment-related events included pancreatitis, increased lipase, neutropenia, tumor lysis syndrome and deep venous thrombosis.
- After year-end, tipifarnib received FDA Breakthrough Therapy Designation for recurrent or metastatic HRAS-mutant HNSCC with HRAS variant allele frequency of at least 20% after platinum-based chemotherapy. This designation does not assure regulatory approval.
- After year-end, the company announced plans for a Phase 1/2 tipifarnib combination study with a PI3 kinase alpha inhibitor in the second half of 2021 and disclosed that KO-539 was advancing into an 800 mg dose cohort after no recommended Phase 2 dose was determined at 600 mg.
- In January 2021, Kura entered a collaboration with Illumina to develop and commercialize an HRAS companion diagnostic for tipifarnib.
Key risks, contingencies and unusual items
- COVID-19 caused slower patient screening and enrollment, site restrictions and potential supply and clinical-data risks.
- The company remains dependent on successful clinical development, regulatory approval and commercialization of tipifarnib and KO-539; it expects continued operating losses and has never generated product revenue.
- Additional financing will likely be required. Future equity or convertible-debt financings could dilute stockholders, while debt or partnerships could restrict operations or require relinquishment of rights.
- Companion diagnostics may be required for approval and are subject to separate regulatory approval, development and reimbursement risks.
- Tipifarnib’s U.S. and European composition-of-matter patents expired in 2016, increasing reliance on method-of-use patents and regulatory exclusivity.
- The company relies on third parties for clinical trials, manufacturing, diagnostic development and other critical activities.
- Contractual obligations at year-end totaled $16.9 million, comprising $7.3 million of debt principal, $1.1 million of debt interest and $8.6 million of operating-lease payments. Potential milestone payments under license agreements could reach approximately $80.2 million, plus royalties, if specified events occur.
- The filing reports no material legal proceedings, no off-balance-sheet arrangements and effective internal control over financial reporting, with an unqualified audit opinion.
Important facts for investors to verify
- Whether AIM-HN enrollment and independent radiology-assessed response results support the proposed regulatory pathway and timelines.
- Whether the preliminary KO-539 activity is sustained in larger patient cohorts and whether a safe, biologically effective Phase 2 dose is established.
- The pace of cash burn relative to the $633.3 million year-end liquidity balance and whether management’s runway into 2024 remains achievable.
- Potential dilution from the $75.0 million unused ATM facility, equity incentive plans, outstanding options and the 33,988-share warrant.
- Regulatory progress and commercial readiness of the Illumina HRAS companion diagnostic.
- Patent durability, regulatory exclusivity and competitive developments for tipifarnib and menin-KMT2A inhibitors.